Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Cut to $795.00 by Analysts at Citigroup

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target trimmed by Citigroup from $895.00 to $795.00 in a research note issued to investors on Tuesday,Benzinga reports. The firm currently has a neutral rating on the biopharmaceutical company’s stock.

Several other equities analysts have also recently issued reports on the company. Leerink Partners reaffirmed a “market perform” rating and set a $1,077.00 price objective (down from $1,175.00) on shares of Regeneron Pharmaceuticals in a report on Tuesday, September 24th. Canaccord Genuity Group downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, December 17th. Sanford C. Bernstein lowered their price objective on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating on the stock in a research note on Tuesday, January 7th. Canaccord Genuity Group began coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 17th. They set a “hold” rating and a $165.00 target price for the company. Finally, StockNews.com lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 4th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $1,032.57.

Regeneron Pharmaceuticals Price Performance

REGN stock opened at $690.87 on Tuesday. The firm has a 50 day moving average of $746.43 and a 200-day moving average of $956.18. The company has a market cap of $75.92 billion, a price-to-earnings ratio of 17.10, a PEG ratio of 2.19 and a beta of 0.10. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals has a 12-month low of $666.25 and a 12-month high of $1,211.20.

Institutional Trading of Regeneron Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Rakuten Securities Inc. boosted its position in shares of Regeneron Pharmaceuticals by 380.0% in the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 19 shares during the last quarter. FSA Wealth Management LLC acquired a new position in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at $26,000. Fairfield Financial Advisors LTD acquired a new position in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at $37,000. Ashton Thomas Private Wealth LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter valued at $39,000. Finally, Truvestments Capital LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter worth $39,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.